Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Study connect Webseite durchsuchen
  • NCT03956680

Active, Not Recruiting

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers - CA046-006

Aktualisiert: 13 Dezember, 2023   |   ClinicalTrials.gov

SIND SIE AN DIESER STUDIE INTERESSIERT?
Drucken Sie diese Seite und den Leitfaden zu klinischen Studien aus, damit Sie sie mit Ihrem Arzt besprechen können.
Nutzen Sie unseren Leitfaden zu klinischen Studien, um mehr über die Schritte für die Teilnahme zu erfahren. Informieren Sie sich über die wichtigsten Punkte, über die Sie nachdenken sollten, und die Fragen, die Sie dem Studienteam stellen sollten, bevor Sie sich für eine Teilnahme entscheiden.
Diese Seite drucken CA046-006
Leitfaden herunterladen

SPRACHE AUSWÄHLEN

Studiendetails

  • Phase 1

    Phase

  • Geschlecht(er)

  • 18+

    Altersgruppe

  • Active, Not Recruiting

Behandlungsmöglichkeiten

Studienarme
ZUGEWIESENE BEHANDLUNG
Experimental: BMS-986301 followed by Nivolumab and Ipilimumab therapy
Drug: Ipilimumab, BMS-986301, Nivolumab
Experimental: Part 1A Group 2: BMS-986301 Monotherapy Intratumoral (I-TUMOR) Sub-study
Drug: BMS-986301, Ipilimumab, Nivolumab
Experimental: Part 1A Group 3: BMS-986301 Monotherapy Intravenous (IV) Sub-study
Drug: BMS-986301, Ipilimumab, Nivolumab
Experimental: Part 1B Group 4: Systemic BMS-986301 + Nivolumab + Ipilimumab
Drug: BMS-986301, Ipilimumab, Nivolumab
Experimental: Part 1B Group 5: I-TUMOR BMS-986301 + Nivolumab + Ipilimumab
Drug: BMS-986301, Ipilimumab, Nivolumab

Wichtigste Eignungskriterien

For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant - IO therapy resistant or insensitive tumors - Have at least 1 (intramuscular treatment group) or 2 (intratumoral treatment group) tumor lesions accessible for biopsy - Eastern Cooperative Oncology Group Performance Status of 0 or 1 Exclusion Criteria: - Primary central nervous system malignancy - Participants with other active malignancy requiring concurrent intervention - Uncontrolled or significant cardiovascular disease Other protocol defined inclusion/exclusion criteria could apply.

Wir empfehlen Ihnen dringend, sich an Bristol Myers Squibb zu wenden, um Nebenwirkungen (unerwünschte Ereignisse) zu melden.
Nebenwirkungen (unerwünschte Ereignisse) und andere meldepflichtige Ereignisse werden hier definiert
Nebenwirkungen (unerwünschte Ereignisse) oder Produktqualitätsbeschwerden melden: Medizinische Information